Liquidia Technologies (NASDAQ: LQDA) is one of 119 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Liquidia Technologies to similar companies based on the strength of its valuation, dividends, risk, profitability, earnings, analyst recommendations and institutional ownership.
This is a breakdown of recent ratings and target prices for Liquidia Technologies and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Liquidia Technologies Competitors||771||2751||4933||249||2.54|
Liquidia Technologies currently has a consensus price target of $36.75, indicating a potential upside of 231.38%. As a group, “Surgical & medical instruments” companies have a potential upside of 356.68%. Given Liquidia Technologies’ rivals higher probable upside, analysts clearly believe Liquidia Technologies has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
47.1% of Liquidia Technologies shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 16.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Liquidia Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Liquidia Technologies Competitors||-34.27%||-43.69%||-15.77%|
Valuation & Earnings
This table compares Liquidia Technologies and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Liquidia Technologies||$2.71 million||-$53.14 million||-1.48|
|Liquidia Technologies Competitors||$1.50 billion||$149.21 million||45.11|
Liquidia Technologies’ rivals have higher revenue and earnings than Liquidia Technologies. Liquidia Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Liquidia Technologies rivals beat Liquidia Technologies on 7 of the 12 factors compared.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.